Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes - PACE-CME

Large risk reductions with SGLT inhibitor in HFrEF with or without diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
ESC 2019
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
- Prof. Freek Verheugt
NP metabolism associated with clinical outcomes in HF
NP metabolism associated with clinical outcomes in HF
ESC 2019
NP metabolism associated with clinical outcomes in HF
- Frank Gommans, MD, PhD
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
ESC 2019
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
- Jan Westerink, MD, PhD